Argus
•
May 27, 2026
Zoetis Inc.: Lowering rating to HOLD
Summary
Zoetis Inc., a 2013 spinoff from Pfizer, focuses on the development, manufacture and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals and distri
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: HCA Healthcare, Inc.
May 28, 2026
•
HCA
The Argus Sustainable Growth Theme Model Portfolio
May 28, 2026
•
TT, GOOGL, DE, AAPL, NDAQ, AVGO, ADI, JPM, JNJ, MRK, TXN, MSFT, TFC, GLW, MA, LLY, TRV, SPGI, GE, NVDA, NOC, KO, KMI, AEP, GS, ECL, TMUS, ETN, AMZN, WMT
Analyst Report: Zimmer Biomet Holdings Inc
May 27, 2026
•
ZBH
Market Update: ZBH, BUD, VTRS
May 27, 2026
•
BUD, ZBH, VTRS
IDXX: Raising target price to $613.00
May 27, 2026
•
IDXX
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
